ストックスクリーナーアプリを入手
77.52
2.54%
-2.02
アフターアワーズ：
77.52
前日終値:
$79.54
開ける：
$79.41
24時間の取引高:
279.06K
Relative Volume:
0.58
時価総額：
$5.17B
収益：
-
当期純損益:
$-224.29M
株価収益率:
-19.88
EPS:
-3.9
ネットキャッシュフロー:
$-185.06M
1週間 パフォーマンス:
-4.25%
1か月 パフォーマンス:
+4.69%
6か月 パフォーマンス:
+3.39%
1年 パフォーマンス:
-22.83%
1日の値動き範囲:
$76.95
$79.61
1週間の範囲:
$75.20
$82.81
52週間の値動き範囲:
$55.53
$106.32
Nuvalent Inc Stock (NUVL) Company Profile
NUVL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
77.52 | 5.74B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
381.87 | 96.56B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.58 | 60.08B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.51 | 61.15B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
711.09 | 44.66B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
328.71 | 36.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-04 | 再開されました | Guggenheim | Buy |
| 2025-09-03 | 開始されました | Raymond James | Outperform |
| 2025-08-19 | 開始されました | Piper Sandler | Overweight |
| 2025-03-14 | アップグレード | UBS | Neutral → Buy |
| 2024-12-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-10-24 | 開始されました | UBS | Neutral |
| 2024-08-29 | 開始されました | Barclays | Overweight |
| 2024-04-17 | 開始されました | Jefferies | Buy |
| 2024-04-01 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | 再開されました | Guggenheim | Buy |
| 2024-02-23 | 開始されました | Robert W. Baird | Outperform |
| 2023-09-27 | 開始されました | Stifel | Buy |
| 2023-08-08 | 開始されました | SVB Securities | Market Perform |
| 2023-07-24 | 開始されました | Guggenheim | Buy |
| 2023-01-18 | 開始されました | Wedbush | Outperform |
| 2022-06-24 | 開始されました | BMO Capital Markets | Outperform |
すべてを表示
Nuvalent Inc (NUVL) 最新ニュース
Nuvalent to Participate in the UBS 2025 Virtual Oncology Day - The Malaysian Reserve
What to expect from Nuvalent Inc. in the next 30 daysTrade Ideas & Risk Controlled Swing Trade Alerts - newser.com
Cancer Drug Developer Nuvalent's CEO and CFO to Share Updates at UBS Virtual Oncology Conference - Stock Titan
5,700 Shares in Nuvalent, Inc. $NUVL Acquired by Strs Ohio - MarketBeat
Nuvalent, Inc. (NASDAQ:NUVL) Receives Average Rating of "Buy" from Analysts - MarketBeat
Intraday pattern recognizer results for Nuvalent Inc.Earnings Trend Report & Safe Capital Growth Trade Ideas - newser.com
Nuvalent completes FDA submission for lung cancer drug zidesamtinib - Investing.com India
Analyzing net buyer seller activity in Nuvalent Inc.July 2025 PostEarnings & Risk Managed Investment Entry Signals - newser.com
LifeSci Capital Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $110 - 富途牛牛
Nuvalent completes FDA submission for lung cancer drug zidesamtinib By Investing.com - Investing.com Nigeria
Nuvalent Completes New Drug Application Submission - TipRanks
Nuvalent (NASDAQ:NUVL) CEO Sells $2,135,160.00 in Stock - MarketBeat
Nuvalent, Inc. $NUVL Shares Bought by Voya Investment Management LLC - MarketBeat
Smart tools for monitoring Nuvalent Inc.’s price actionJuly 2025 Setups & Entry and Exit Point Strategies - newser.com
Market Review: Can Nuvalent Inc. beat the S&P 500Market Growth Summary & Pattern Based Trade Signal System - خودرو بانک
Can a trend reversal in Nuvalent Inc. lead to recovery2025 Growth vs Value & Daily Momentum Trading Reports - newser.com
Is Nuvalent Inc. reversing from oversold territoryJuly 2025 Weekly Recap & Fast Entry High Yield Stock Tips - newser.com
Aug Patterns: Does Nuvalent Inc have a sustainable dividendShare Buyback & Low Drawdown Investment Strategies - خودرو بانک
Aug Final Week: Does Nuvalent Inc stock benefit from AI growthJuly 2025 Spike Watch & Target Return Focused Picks - خودرو بانک
Is this a good reentry point in Nuvalent Inc.Portfolio Risk Summary & Risk Adjusted Swing Trade Ideas - newser.com
What momentum shifts mean for Nuvalent Inc.July 2025 Breakouts & Smart Money Movement Tracker - newser.com
Risk adjusted return profile for Nuvalent Inc. analyzedDollar Strength & Real-Time Buy Signal Alerts - newser.com
Does Nuvalent’s Recent FDA Breakthrough Designation Signal a New Opportunity for Investors in 2025? - Yahoo Finance
Chart overlay techniques for tracking Nuvalent Inc.Weekly Profit Summary & Risk Managed Investment Entry Signals - newser.com
Henry E. Pelish Sells 3,725 Shares of Nuvalent (NASDAQ:NUVL) Stock - MarketBeat
Voya Investment Management LLC Has $8.53 Million Holdings in Nuvalent, Inc. $NUVL - Defense World
Sector ETF performance correlation with Nuvalent Inc.Market Trend Review & Smart Allocation Stock Reports - newser.com
Nuvalent (NUVL): Assessing Valuation Following Subtle Shifts in Investor Sentiment - Yahoo Finance
Surprises Report: Should I buy Nuvalent Inc stock nowMarket Sentiment Summary & Stepwise Trade Signal Implementation - خودرو بانک
Aug Selloffs: Is Nuvalent Inc stock a value trap2025 Pullback Review & Consistent Income Trade Recommendations - خودرو بانک
Aug Levels: Is Nuvalent Inc stock a value trapWeekly Stock Analysis & Risk Controlled Stock Alerts - خودرو بانک
Dividend Watch: Should I set a stop loss on Nuvalent IncJuly 2025 Levels & AI Forecast Swing Trade Picks - خودرو بانک
Stock Analysis: Should I buy Nuvalent Inc stock now2025 Market Sentiment & Free Verified High Yield Trade Plans - خودرو بانک
Tech Rally: Can RFAI grow without external fundingJuly 2025 Sentiment & High Conviction Investment Ideas - خودرو بانک
Nuvalent Inc (NUVL) 財務データ
収益
当期純利益
現金流量
EPS
Nuvalent Inc (NUVL) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Porter James Richard | President and CEO |
Sep 15 '25 |
Sale |
79.08 |
27,000 |
2,135,055 |
249,062 |
| Pelish Henry E. | Chief Scientific Officer |
Sep 10 '25 |
Option Exercise |
26.94 |
3,725 |
100,354 |
69,688 |
| Pelish Henry E. | Chief Scientific Officer |
Sep 10 '25 |
Sale |
78.83 |
3,725 |
293,642 |
65,963 |
2.43%
大文字化:
|
ボリューム (24 時間):